Clinical Trial Update: Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial update for NFC-1 in adolescents with genetic disorders impacting mGluR and ADHD has completed with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Disorder with Hyperactivity

Drugs mentioned

• NFC-1

Snippet

Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-03-29